Sands Capital Life Sciences Pulse Fund II, L.P.

13D and 13G Filings

13D/G filings: 13D on 1 security, 13G on 3 securities
Location: Arlington, VA
CIK: 0001875620
Form D filings: 1 filing
All SEC filings: View on sec.gov

Issuer	Symbol	CUSIP	% of Class	Shares	Form	Filed
Inhibikase Therapeutics, Inc. 13G/A Amendment 3 IKT · 45719W205	IKT	45719W205	9.3%	13,018,965	13G/A Amendment 3	8/13/2026 Event 6/30/2026
Sands Capital Life Sciences Pulse Fund II, L.P.			9.3%	13,018,965
Sands Capital Alternatives, LLC			9.3%	13,018,965
Sands Frank M.			9.3%	13,018,965
Acrivon Therapeutics, Inc. 13G/A Amendment 4 ACRV · 004890109	ACRV	004890109	5.3%	2,289,271	13G/A Amendment 4	8/13/2026 Event 6/30/2026
Sands Capital Life Sciences Pulse Fund II, L.P.			5.3%	2,289,271
Sands Capital Alternatives, LLC			5.3%	2,289,271
Sands Frank M.			5.3%	2,289,271
Alamar Biosciences, Inc. 13D/A Amendment 1 ALMR · 010911105	ALMR	010911105	6.1%	4,230,926	13D/A Amendment 1	7/7/2026 Event 7/5/2026
Sands Capital Life Sciences Pulse Fund II, L.P.			6.1%	4,230,926
Sands Capital Alternatives, LLC			6.1%	4,230,926
Sands Frank M.			6.1%	4,230,926
Alamar Biosciences, Inc. 13D ALMR · 010911105	ALMR	010911105	6.3%	4,230,926	13D	4/23/2026 Event 4/16/2026
Sands Capital Life Sciences Pulse Fund II, L.P.			6.3%	4,230,926
Sands Capital Alternatives, LLC			6.3%	4,230,926
Sands Frank M.			6.3%	4,230,926
Inhibikase Therapeutics, Inc. 13G/A Amendment 2 IKT · 45719W205	IKT	45719W205	10.8%	13,018,965	13G/A Amendment 2	2/13/2026 Event 12/31/2025
Sands Capital Life Sciences Pulse Fund II, L.P.			10.8%	13,018,965
Sands Capital Alternatives, LLC			10.8%	13,018,965
Sands Frank M.			10.8%	13,018,965
Beta Bionics, Inc. 13G/A Amendment 1 BBNX · 08659B102	BBNX	08659B102	8.2%	3,570,113	13G/A Amendment 1	8/13/2025 Event 6/30/2025
Sands Capital Life Sciences Pulse Fund II. L.P.			8.2%	3,570,113
Sands Capital Alternatives, LLC			8.2%	3,570,113
Sands Frank M.			8.2%	3,570,113
Inhibikase Therapeutics, Inc. 13G/A Amendment 1 IKT · 45719W205	IKT	45719W205	14.7%	10,950,000	13G/A Amendment 1	8/13/2025 Event 6/30/2025
Sands Capital Life Sciences Pulse Fund II, L.P.			14.7%	10,950,000
Sands Capital Alternatives, LLC			14.7%	10,950,000
Sands Frank M.			14.7%	10,950,000
Acrivon Therapeutics, Inc. 13G/A Amendment 3 ACRV · 004890109	ACRV	004890109	6.8%	2,122,605	13G/A Amendment 3	8/13/2025 Event 6/30/2025
Sands Capital Life Sciences Pulse Fund II, L.P.			6.8%	2,122,605
Sands Capital Alternatives, LLC			6.8%	2,122,605
Sands Frank M.			6.8%	2,122,605
Beta Bionics, Inc. 13G BBNX · 08659B102	BBNX	08659B102	7.3%	3,154,409	13G	4/9/2025 Event 4/2/2025
Sands Capital Life Sciences Pulse Fund II. L.P.			7.3%	3,154,409
Sands Capital Ventures, LLC			7.3%	3,154,409
Frank M. Sands			7.3%	3,154,409

Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.